Anti factor Xa measurement

Hirsh J, Warkentin TE, Shaughnessy SG, et al: Heparin and low-molecular-weight heparin. Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety.. Chest. 2001; 119:64S-94S.

Kitchen S, Theaker J, & Preston FE: Monitoring unfractionated heparin therapy: relationship between eight anti-Xa assays and a protamine titration assay. Blood Coagulation and Fibrinolysis 2000; 11(2):137-144.

Laposata M, Green D, Van Cott EM, et al: College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med 1998; 122(9):799-807.

Olson JD, Arkin CF, Brandt JT, et al: College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med 1998; 122(9):782-798.

Monagle P, Chan A, Massicotte P, et al: Antithrombotic therapy in children: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126(3 Suppl):645S-687S.

Greaves M: Limitation of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostatis. Thromb Haemost 2002; 87(1):163-4.

Becker RC, Spencer FA, Gibson M, et al: Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J 2002; 143(5):753-759.